Navigation Links
Somanetics Reports Second Quarter Results and Extension of Exclusive Distribution Agreement With Covidien

- Somanetics has signed a three-year extension of its exclusive distribution agreement with Covidien for Europe, the Middle East and Africa.

- Somanetics received 510(k) clearance from the U.S. Food and Drug Administration to expand the labeling for its INVOS(R) Cerebral/Somatic Oximeter. The new labeling includes three new marketing claims, including a claim of improved outcomes after cardiac or major general surgery when the INVOS System is used to manage therapies in patients weighing more than 2.5 kilograms.

- Somanetics' INVOS System was featured in 25 abstracts that focused on applications of the technology in the neonatal intensive care unit at the Pediatric Academic Societies' annual conference held in May.

- Net revenues for the second quarter were $11.8 million, primarily due to lower than expected hospital capital equipment spending on INVOS System hardware in the U.S. market.

- Net income for the second quarter was $1.8 million, or $0.14 per diluted share.

TROY, Mich., June 17 /PRNewswire-FirstCall/ -- Somanetics Corporation (Nasdaq: SMTS) today reported net revenues of $11.8 million for the second quarter ended May 31, 2009, compared with revenues of $12.7 million in the same period of 2008. For the six months ended May 31, 2009, net revenues increased seven percent to $23.0 million from $21.4 million in the same period last year.

U.S. net revenues were $9.3 million, compared with $10.2 million in the second quarter of fiscal 2008. International net revenues were $2.5 million, flat with the same period in 2008. For the six-month period, U.S. net revenues increased two percent to $18.1 million from $17.7 million and international revenues increased 31 percent from $3.8 million to $4.9 million.

"Amid continued weakness in the U.S. economy, hospitals restricted their capital spending for the INVOS System to a greater extent than we had anticipated," said Bruce Barrett, Somanetics' president and chief executive officer. "Since most of our INVOS System placements for revenue in the U.S. market are in pediatric and neonatal ICUs, capital budget constraints also are impacting the start up of new neonatal and pediatric accounts and associated sensor sales."

"On the positive side, adult sensor demand was strong, largely off-setting the shortfall in pediatric and neonatal sensor volume," said Barrett. "We experienced our strongest sequential growth in more than two years in the U.S. market for adult sensors in the second quarter. INVOS System hardware and disposable sensor purchases by our international distribution partners are on track for the year."

Second quarter income before income taxes was $2.9 million, compared to $4.8 million for the second quarter of 2008. Net income was $1.8 million, or $0.14 per diluted share, compared with net income of $3.1 million, or $0.21 per diluted share, in the second quarter of 2008.

For the six months ended May 31, 2009, income before income taxes was $5.0 million compared to $6.5 million in the comparable period of fiscal 2008. Net income was $3.1 million, or $0.24 per diluted share for the first half of 2009, compared with net income of $4.1 million, or $0.28 per diluted share, for the first half of 2008.

Gross margin was 86 percent in the second quarter and first six months of fiscal 2009, compared with 87 percent for the respective periods of 2008. Cash, marketable securities and long-term investments at May 31, 2009 totaled $74.1 million, with no borrowings.

"From an earnings perspective, we finished the first half of our fiscal year modestly ahead of our internal plan due to lower than planned spending," said Barrett. "We have increased our investments by 11 percent compared to last year to support our entry into the neonatal ICU and pursue development and launch of our new Vital Sync System, but this increase is below our plan primarily due to the addition of personnel at a slower pace than we had projected."

Extension of International Distribution Agreement with Covidien

Somanetics also announced today that it has extended its long-standing exclusive distribution agreement with Covidien to distribute Somanetics' INVOS Cerebral/Somatic Oximeter products in Europe, the Middle East and Africa. The three-year extension will go into effect on February 16, 2010, when the current agreement expires. At that time, transfer prices will change and incremental revenue recognized by Somanetics in the first full year of the extension is estimated to be between $2.5 million and $3.0 million.

"We are very pleased to extend this important relationship with Covidien under terms that both parties embrace," Barrett said.

Expanded FDA Labeling Claims

Somanetics received 510(k) clearance from the U.S. Food and Drug Administration to expand the labeling for its INVOS Cerebral/Somatic Oximeter. The new labeling includes three new marketing claims based on results published in peer-reviewed literature as follows:

  • The measurement of regional cerebral oxygen saturation (rSO2) is an indication of whether oxygen delivery to the brain is adequate. Prolonged declines in rSO2 are indicative of, or may result in, potential brain injury.

  • When used as an indication of compromised cerebral oxygenation, interventions to return the patient's rSO2 to baseline using the INVOS System have been shown to improve outcomes after surgery.

  • In neonates, infants and children, cerebral and somatic rSO2 provide noninvasive indications of oxygen changes in the cerebral and peripheral circulatory systems and may provide an early indication of oxygen deficits associated with impending shock states and anaerobiosis.

"Early indications are that this new labeling is going to help us continue to drive adoption of our technology, especially in adult cardiac surgery," said Barrett.

Launch of the Vital Sync(TM) System

Last November, Somanetics acquired substantially all of the assets of Gainesville, Fla.-based ICU Data Systems, Inc., which developed a patented technology that integrates data from a broad array of hospital bedside devices, such as physiological monitors and ventilators, into a single bedside display for comparison, data management and storage. The technology has been further developed and is being commercially launched by Somanetics under the product name "Vital Sync(TM)."

"The Vital Sync System addresses the unmet need at the bedside to aggregate and intelligently display data from a variety of machines to support clinical decision making," said Barrett. "We believe the system can help speed recognition and understanding of developing clinical problems and prompt earlier intervention. In doing so, it should help improve patient safety and care."

Somanetics has initiated its marketing launch and plans to make its first installations of the Vital Sync System beginning later in June.

Business Outlook

"Our new business activity remains strong, but because hospitals are delaying release of budgeted capital dollars and unbudgeted capital dollars are largely unavailable, we are lowering our guidance based on the assumption that INVOS hardware revenues in the U.S. market will remain soft for the balance of the year," Barrett said.

Based on this expectation, the Company's current guidance is:

  • Fiscal 2009 net revenues between $50 million and $52 million.

  • Gross margin of approximately 86 percent and operating margin of approximately 20 percent.

  • Fiscal 2009 income before income taxes in the range of $11.2 million to $11.6 million.

Current estimates are based on market and economic conditions, including the assumption that the current economic downturn continues throughout fiscal 2009, and Somanetics' current plans to invest in several areas of its business. Such investments include clinical research, medical education, research and development projects focused on the pediatric and neonatal ICU markets, the continued development and market launch of the Vital Sync System and the addition of sales personnel in the U.S. and international markets. Somanetics undertakes no obligation to update its estimates.

Somanetics to Host Conference Call

Somanetics will web cast its 2009 second quarter conference call at 10:00 a.m. (ET) today. To join the webcast, visit the Presentations and Webcasts page in the Investor Relations section of Somanetics' website at and click on the "Q2 2009 Somanetics Corporation Earnings Conference Call" link. The call also will be archived on the website.

About Somanetics

Somanetics Corporation (Nasdaq: SMTS) develops, manufactures and markets the INVOS(R) Cerebral/Somatic Oximeter which noninvasively provides accurate, real-time blood oxygen measurements in patients greater than 2.5 kilograms, and trend monitoring of this parameter for individuals of any weight. The INVOS System is the only commercially-available cerebral/somatic oximeter proven to improve outcomes in patients above 2.5 kilograms, and is the only cerebral/somatic oximeter system cleared for use on neonates less than 2.5 kg. Surgeons, anesthesiologists and other medical professionals can use data provided by the INVOS System, in conjunction with other available data, to identify oxygen imbalances in brain or other body tissue beneath the sensor and take necessary corrective action, potentially improving patient outcomes and reducing the costs of care. The INVOS System is the clinical reference standard in cerebral/somatic oximetry, with an 11-year market track record, more than 700 clinical references and implementation at more than 700 U.S. hospitals. Somanetics also is developing the Vital Sync(TM) System, a device that integrates data from bedside devices into a single system for enhanced patient assessment and decision making, data management and data storage. Somanetics supports its customers through a direct U.S. sales force and clinical education team. Covidien markets INVOS System products in Europe, Canada, the Middle East and Africa and Edwards Lifesciences represents INVOS System products in Japan. For more information visit

Safe-Harbor Statement

Except for historical information contained herein, the matters discussed in this news release, including financial guidance for fiscal year 2009, are forward-looking statements, the accuracy of which is necessarily subject to risks and uncertainties. Actual results may differ significantly from results discussed in the forward-looking statements and may be affected by, among other things, economic conditions in general and in the healthcare market, including the recent global economic crisis, the demand for and market acceptance of our products in existing market segments and in new market segments we plan to pursue, our current dependence on the INVOS Cerebral/Somatic Oximeter and disposable sensors, our dependence on distributors for a substantial portion of our sales, our dependence on single-source suppliers, potential competition, the effective management of our growth, our ability to attract and retain key personnel, the potential for products liability claims, government regulation of our business, the challenges associated with developing new products and obtaining and maintaining regulatory approvals if necessary, research and development activities, the lengthy sales cycle for our products, sales employee turnover, changes in our actual or estimated future income, changes in accounting rules, enforceability and the costs of enforcement of our patents, potential infringements of others' patents, the effect of acquisitions and the other factors set forth from time to time in Somanetics' Securities and Exchange Commission filings, including Somanetics' 2008 Annual Report on Form 10-K filed on February 11, 2009 and its first quarter 2009 Quarterly Report on Form 10-Q filed on March 31, 2009.

(Tables to follow)


                                             May 31,              November 30,
                                              2009                    2008
    ASSETS                                 (Unaudited)             (Audited)
           Cash and cash equivalents     $  9,542,614          $  37,166,141
           Marketable securities            30,416,677             19,992,545
           Accounts receivable               7,755,698              7,862,103
           Inventory                         3,443,414              2,960,422
           Prepaid expenses                    336,004                597,460
           Accrued interest receivable         175,117                 16,667
           Deferred tax asset - current       164,615                164,615
                Total current assets       51,834,139             68,759,953
      Demonstration and no capital cost
       sales equipment at customers          4,151,736              3,919,296
           Machinery and equipment           1,834,989              1,638,597
           Furniture and fixtures              535,049                504,485
           Leasehold improvements              197,450                197,450
                  Total                     6,719,224              6,259,828
           Less accumulated depreciation
            and amortization                (3,804,637)            (3,418,697)
                Net property and equipment   2,914,587              2,841,131
           Long-term investments            34,092,001             12,837,710
           Deferred tax asset - non-current  1,672,977              1,587,977
           Intangible assets, net              240,160                246,318
           Goodwill                          1,679,713              1,679,713
           Other                                15,000                 15,000
                  Total other assets       37,699,851             16,366,718
    TOTAL ASSETS                         $  92,448,577          $  87,967,802

           Accounts payable            $       920,512      $       1,271,058
           Accrued liabilities                 996,368              1,848,672
                Total current liabilities    1,916,880              3,119,730
           Preferred shares; authorized,
            1,000,000 shares of $.01 par
            value; no shares issued or
           Common shares; authorized,
            20,000,000 shares of $.01 par
            value; issued and outstanding,
            12,088,962 shares at
            May 31, 2009, and
            12,034,074 shares at
            November 30, 2008                   120,890               120,341
           Additional paid-in capital        93,933,637            91,330,305
           Accumulated deficit               (3,522,830)           (6,602,574)
                  Total shareholders'
                   equity                    90,531,697            84,848,072
     SHAREHOLDERS' EQUITY             $      92,448,577    $       87,967,802


                                  Three Months                 Six Months
                                  Ended May 31,               Ended May 31,
                               2009         2008         2009           2008
    NET REVENUES          $11,831,560   $12,740,063  $22,986,914   $21,433,338
    COST OF SALES           1,603,755     1,679,256    3,184,236     2,696,081
        Gross Margin       10,227,805    11,060,807   19,802,678    18,737,257

      Research, development
       and engineering        485,780       231,901      919,742       562,337
      Selling, general and
       administrative       7,184,010     6,769,838   14,487,908    13,267,984
         Total operating
          expenses          7,669,790     7,001,739   15,407,650    13,830,321

    OPERATING INCOME        2,558,015     4,059,068    4,395,028     4,906,936

      Interest income         328,836       700,685      600,221     1,635,102
       Total other income     328,836       700,685      600,221     1,635,102
     INCOME TAXES           2,886,851     4,759,753   4,995,249     6,542,038

    INCOME TAX EXPENSE     (1,109,286)   (1,707,501)  (1,915,505)  (2,461,356)

    NET INCOME             $1,777,565    $3,052,252   $3,079,744   $4,080,682

     SHARE - BASIC         $     0.15    $     0.23    $     0.26   $     0.31

     SHARE - DILUTED       $     0.14    $     0.21    $     0.24   $     0.28

     OUTSTANDING - BASIC   12,056,844    13,145,234    12,047,707   13,297,128

     DILUTED               12,923,857    14,220,477    12,923,141   14,380,547

SOURCE Somanetics Corporation
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Somanetics Corporation to Release Second Quarter 2009 Financial Results and Host Conference Call June 17, 2009
2. 25 Clinical Abstracts at National Conference Spotlight Clinical Utility of Somanetics INVOS System in Neonates
3. Somanetics Announces New FDA 510(K) Clearance
4. Somanetics Reports Record Net Revenues and Income Before Income Taxes for Fourth Quarter and Fiscal 2008
5. Somanetics Corporation to Release Fourth Quarter and Fiscal 2008 Financial Results and Host Conference Call January 21, 2009
6. Somanetics Corporation to Present at Rodman & Renshaw Annual Global Investment Conference
7. Somanetics Announces Share Repurchase Program Increased By $15 Million
8. Somanetics Receives 510(k) Clearance From the FDA to Expand INVOS System Labeling
9. Somanetics Corporation to Present at Citigroup 2008 Healthcare Conference
10. Somanetics Announces Share Repurchase Program Increased by $15 Million
11. Somanetics Announces Share Repurchase Program
Post Your Comments:
(Date:12/1/2015)... ... ... Growth in medical payments per workers’ compensation claim in Louisiana slowed from 2011 ... according to a recent study by the Workers Compensation Research Institute (WCRI). , ... per claim with more than seven days of lost time continued to be higher ...
(Date:12/1/2015)... Wayland, MA (PRWEB) , ... December 01, 2015 , ... ... adults has a tattoo — a number even greater among Millennials (a whopping one ... there are more and more people who are dissatisfied with their ink. In fact, ...
(Date:12/1/2015)... ... December 01, 2015 , ... ... technicians must mark the film for accurate interpretation by the radiologist. The marking ... an inventor from Sacramento, Calif., has found a way to alleviate this problem. ...
(Date:12/1/2015)... ... 01, 2015 , ... Next IT Healthcare, the leader in ... this year’s Fierce Innovation Awards: Healthcare Edition, an awards program from the publisher ... in the category of Digital Solutions for its innovative, industry-leading product, Alme Health ...
(Date:12/1/2015)... ... December 01, 2015 , ... ... Effective Post-Affiliation Integration ,” addresses a main “pain point” for merging or aligning ... results, once a deal is signed. This quick-read guidance suggests that failing ...
Breaking Medicine News(10 mins):
(Date:12/1/2015)... , Dec. 1, 2015 Relmada Therapeutics, Inc. ... treatment of chronic pain, announced today that the company will ... be held December 1-3 at the Luxe Sunset Boulevard Hotel ... Traversa , CEO of Relmada Therapeutics, will present on Thursday, ... Time). . Please register at least 10 ...
(Date:12/1/2015)... 2015 CytRx Corporation (NASDAQ: CYTR ), ... today announced that it has reached its enrollment target ... 3 clinical trial of aldoxorubicin in patients with previously ... be completed in Q1 2016. The Phase 3 trial is ... Protocol Assessment from the FDA at 79 sites in ...
(Date:12/1/2015)... , Dec. 1, 2015  Today, ... the launch of CareFront, a first-of-its-kind population health ... diagnosed with cancer. Designed to be built into ... cancer patients with resources for their care and ... program also offers tools to help patients understand ...
Breaking Medicine Technology: